Cell Line Development Market size to exceed $11.6bn by 2028

Cell Line Development Market size is set to surpass USD 11.6 billion by 2028, according to a new research report by Global Market Insights Inc.
 

Increasing technological advancements in cell line development coupled with innovations in biologics due to patent expiration will drive the industry growth. Additionally, growing demand for monoclonal antibodies will further propel the market revenue.
 

Worldwide increase in vaccine production will fuel the market progression

Rise in the vaccine production across the globe is one of the major factors rendering the cell line development market demand. This is owing to the rising awareness about immunization for improving human health. This vaccination process has eradicated various deadly and infectious diseases over time. Vaccination plays a key role in maintaining sustainable health of people. Thus, vaccination is administered to people of various age groups that strengthen their immune system and give them protection against various diseases. Therefore, vaccine development has a huge potential to transform health by eradicating various diseases. Such scenarios have increased the investments towards development of new vaccines.
 

Cell line development plays a crucial role in vaccine production. The cell lines provide an appropriate environment to the organism against which vaccine needs to be developed. They maintain the infectability, stability and performance quality of the organism, making vaccine production easy. These advantages of cell lines in vaccine production will surge the demand for cell line development.
 

Cell line production on a large scale will drive the business landscape

Based on the product, the cell line development market is segmented into reagents and media, equipment, and accessories and consumables. the equipment segment is set to register around 10% CAGR over projected timeline. This is attributed to the increased production of cell lines for various applications such as bio-production of vaccines, biologics, biosimilars, mAbs and therapeutic protein. Cell line development involves multiple complex processes that require consistency and reproducibility. This equipment helps in large scale manufacturing of biotherapeutics.
 

Browse key industry insights spread across 238 pages with 335 market data tables & 16 figures & charts from the report, “Cell Line Development Market Analysis By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope, Electroporators, FACS}, Accessories & Consumables), Source (Mammalian, Non-mammalian {Insects, Amphibians}), Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/cell-line-development-market-report
 

Rise in adoption of non-mammalian cell lines will boost the industry statistics

Cell line development market based on source is bifurcated into mammalian and non-mammalian cell lines. The non-mammalian cell lines segment was valued at USD 1.5 billion in 2021. This is due to adoption of non-mammalian cell lines for vaccine production. Non-mammalian cell lines utilize different insect and amphibian systems that allow constitutive or inducible production of recombinant proteins. These cell lines can efficiently express recombinant proteins, thus proving an excellent platform for the production of recombinant antibodies. Such advantages of non-mammalian cell lines will propel the market expansion.
 

Increasing use of monoclonal antibodies will upsurge the market forecasts

Hybridomas segment is garnered 27.8% revenue share in 2021 and projected to record a lucrative CAGR in the coming years. This is credited to increasing use of monoclonal antibodies (mAbs) for targeted therapies. Hybridoma cell lines are used for the production of monoclonal antibodies. Hybridoma cells are formed by fusing short-lived antibody-producing B-cell with immortal myeloma/tumor cells. Monoclonal antibodies help in improving life of patients suffering from cancer, autoimmune diseases, and anti-inflammatory disorders. These are immortalized cells ensure antibody production via continuously dividing cells. The hybridoma cells ensure large scale production of antibodies for various diagnostic and therapeutic purpose. Such scenarios demand for cell line development.
 

Rise in development of new drugs will spur the industry expansion

Cell line development market based on application is categorized into bioproduction, drug discovery, tissue engineering, toxicity testing, and research. The drug discovery segment accounted for around USD 683 million in 2021. This is attributed to increasing demand for the development efficient and precise medication to tackle surging number of various disorders. Cell line development is a crucial step for assessing the efficiency of chemical composition, toxicity, drug discovery and testing. The cell line is used in drug discovery to reduce time, effort, cost that reduces the chance of drugs failing at the clinical trial stage. Such collaborations for new product launches increase the demand for cell line development.
 

New drug developments and approvals in Europe will enhance the industry progression

Europe cell line development market accounted for 26.5% revenue share in 2021 and is set to register a significant CAGR through 2028. This is attributed to presence of advanced and well-established healthcare infrastructure and increasing R&D expenditure. In addition, the region also includes wide array of institutes involved in biomedical and pharmaceutical R&D. The institutes and major market players are involved in new drug development are funded by various agencies.
 

This drug is a next-generation Bruton’s Tyrosine Kinase (BTK) inhibitor involved in the treatment of patients suffering chronic lymphocytic leukemia. Such scenarios in will positively influence the regional market revenue.
 

Major leaders are focusing on strategies & launching innovative products to capture a higher market share

Some of the major industry players operating in the cell line development market are Advanced Instruments, LLC., AGC Biologics, Catalent, Corning Inc., Cyagen, Cytiva, Eurofins, FUJIFILM Diosynth Biotechnologies, GenScript Biotech Corporation, Horizon Discovery, Imgenex, Lonza, NAEJA RGM Pharmaceuticals, Novartis, Premas Biotech, Probiogen, PromoCell, Rentschler Biopharma SE, Samsung Biologics, Sartorius AG, Selexis SA, Vista Biologics, Syngene International Limited, Thermo Fisher Scientific Inc., Vista Biologicals, and WuXi AppTec among others.
 

For instance, Thermo Fisher Scientific introduced New Quick to Clinic Solution to help biologic drug developers at BIO Digital 2021. It accelerates the process of preclinical drug development by helping companies to reach Phase I of clinical trials. This new product development helped company to gain more revenue and strengthen its position in the industry.